Cargando…

New highly sensitive rodent and human tests for soluble amyloid precursor protein alpha quantification: preclinical and clinical applications in Alzheimer’s disease

BACKGROUND: Amyloid precursor protein (APP), a key molecule in Alzheimer’s disease (AD), is metabolized in two alternative cleavages, generating either the amyloidogenic peptides involved in AD pathology or the soluble form of APP (sAPPα). The level of amyloidogenic peptides in human cerebrospinal f...

Descripción completa

Detalles Bibliográficos
Autores principales: Rose, Christiane, Peoc’h, Katell, Chasseigneaux, Stéphanie, Paquet, Claire, Dumurgier, Julien, Bourasset, Fanchon, Calon, Frédéric, Laplanche, Jean-Louis, Hugon, Jacques, Allinquant, Bernadette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3418197/
https://www.ncbi.nlm.nih.gov/pubmed/22824057
http://dx.doi.org/10.1186/1471-2202-13-84
_version_ 1782240607774703616
author Rose, Christiane
Peoc’h, Katell
Chasseigneaux, Stéphanie
Paquet, Claire
Dumurgier, Julien
Bourasset, Fanchon
Calon, Frédéric
Laplanche, Jean-Louis
Hugon, Jacques
Allinquant, Bernadette
author_facet Rose, Christiane
Peoc’h, Katell
Chasseigneaux, Stéphanie
Paquet, Claire
Dumurgier, Julien
Bourasset, Fanchon
Calon, Frédéric
Laplanche, Jean-Louis
Hugon, Jacques
Allinquant, Bernadette
author_sort Rose, Christiane
collection PubMed
description BACKGROUND: Amyloid precursor protein (APP), a key molecule in Alzheimer’s disease (AD), is metabolized in two alternative cleavages, generating either the amyloidogenic peptides involved in AD pathology or the soluble form of APP (sAPPα). The level of amyloidogenic peptides in human cerebrospinal fluid (CSF) is considered to be a biomarker of AD, whereas the level of sAPPα in CSF as a biomarker has not been clearly established. sAPPα has neurotrophic and neuroprotective properties. Stimulating its formation and secretion is a promising therapeutic target in AD research. To this end, very sensitive tests for preclinical and clinical research are required. METHODS: The tests are based on homogenous time-resolved fluorescence and require no washing steps. RESULTS: We describe two new rapid and sensitive tests for quantifying mouse and human sAPPα. These 20 μl-volume tests quantify the levels of: i) endogenous mouse sAPPα in the conditioned medium of mouse neuron primary cultures, as well as in the CSF of wild-type mice, ii) human sAPPα in the CSF of AD mouse models, and iii) human sAPPα in the CSF of AD and non-AD patients. These tests require only 5 μl of conditioned medium from 5 × 10(4) mouse primary neurons, 1 μl of CSF from wild-type and transgenic mice, and 0.5 μl of human CSF. CONCLUSIONS: The high sensitivity of the mouse sAPPα test will allow high-throughput investigations of molecules capable of increasing the secretion of endogenous sAPPα in primary neurons, as well as the in vivo validation of molecules of interest through the quantification of sAPPα in the CSF of treated wild-type mice. Active molecules could then be tested in the AD mouse models by quantifying human sAPPα in the CSF through the progression of the disease. Finally, the human sAPPα test could strengthen the biological diagnosis of AD in large clinical investigations. Taken together, these new tests have a wide field of applications in preclinical and clinical studies.
format Online
Article
Text
id pubmed-3418197
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-34181972012-08-14 New highly sensitive rodent and human tests for soluble amyloid precursor protein alpha quantification: preclinical and clinical applications in Alzheimer’s disease Rose, Christiane Peoc’h, Katell Chasseigneaux, Stéphanie Paquet, Claire Dumurgier, Julien Bourasset, Fanchon Calon, Frédéric Laplanche, Jean-Louis Hugon, Jacques Allinquant, Bernadette BMC Neurosci Methodology Article BACKGROUND: Amyloid precursor protein (APP), a key molecule in Alzheimer’s disease (AD), is metabolized in two alternative cleavages, generating either the amyloidogenic peptides involved in AD pathology or the soluble form of APP (sAPPα). The level of amyloidogenic peptides in human cerebrospinal fluid (CSF) is considered to be a biomarker of AD, whereas the level of sAPPα in CSF as a biomarker has not been clearly established. sAPPα has neurotrophic and neuroprotective properties. Stimulating its formation and secretion is a promising therapeutic target in AD research. To this end, very sensitive tests for preclinical and clinical research are required. METHODS: The tests are based on homogenous time-resolved fluorescence and require no washing steps. RESULTS: We describe two new rapid and sensitive tests for quantifying mouse and human sAPPα. These 20 μl-volume tests quantify the levels of: i) endogenous mouse sAPPα in the conditioned medium of mouse neuron primary cultures, as well as in the CSF of wild-type mice, ii) human sAPPα in the CSF of AD mouse models, and iii) human sAPPα in the CSF of AD and non-AD patients. These tests require only 5 μl of conditioned medium from 5 × 10(4) mouse primary neurons, 1 μl of CSF from wild-type and transgenic mice, and 0.5 μl of human CSF. CONCLUSIONS: The high sensitivity of the mouse sAPPα test will allow high-throughput investigations of molecules capable of increasing the secretion of endogenous sAPPα in primary neurons, as well as the in vivo validation of molecules of interest through the quantification of sAPPα in the CSF of treated wild-type mice. Active molecules could then be tested in the AD mouse models by quantifying human sAPPα in the CSF through the progression of the disease. Finally, the human sAPPα test could strengthen the biological diagnosis of AD in large clinical investigations. Taken together, these new tests have a wide field of applications in preclinical and clinical studies. BioMed Central 2012-07-23 /pmc/articles/PMC3418197/ /pubmed/22824057 http://dx.doi.org/10.1186/1471-2202-13-84 Text en Copyright ©2012 Rose et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Methodology Article
Rose, Christiane
Peoc’h, Katell
Chasseigneaux, Stéphanie
Paquet, Claire
Dumurgier, Julien
Bourasset, Fanchon
Calon, Frédéric
Laplanche, Jean-Louis
Hugon, Jacques
Allinquant, Bernadette
New highly sensitive rodent and human tests for soluble amyloid precursor protein alpha quantification: preclinical and clinical applications in Alzheimer’s disease
title New highly sensitive rodent and human tests for soluble amyloid precursor protein alpha quantification: preclinical and clinical applications in Alzheimer’s disease
title_full New highly sensitive rodent and human tests for soluble amyloid precursor protein alpha quantification: preclinical and clinical applications in Alzheimer’s disease
title_fullStr New highly sensitive rodent and human tests for soluble amyloid precursor protein alpha quantification: preclinical and clinical applications in Alzheimer’s disease
title_full_unstemmed New highly sensitive rodent and human tests for soluble amyloid precursor protein alpha quantification: preclinical and clinical applications in Alzheimer’s disease
title_short New highly sensitive rodent and human tests for soluble amyloid precursor protein alpha quantification: preclinical and clinical applications in Alzheimer’s disease
title_sort new highly sensitive rodent and human tests for soluble amyloid precursor protein alpha quantification: preclinical and clinical applications in alzheimer’s disease
topic Methodology Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3418197/
https://www.ncbi.nlm.nih.gov/pubmed/22824057
http://dx.doi.org/10.1186/1471-2202-13-84
work_keys_str_mv AT rosechristiane newhighlysensitiverodentandhumantestsforsolubleamyloidprecursorproteinalphaquantificationpreclinicalandclinicalapplicationsinalzheimersdisease
AT peochkatell newhighlysensitiverodentandhumantestsforsolubleamyloidprecursorproteinalphaquantificationpreclinicalandclinicalapplicationsinalzheimersdisease
AT chasseigneauxstephanie newhighlysensitiverodentandhumantestsforsolubleamyloidprecursorproteinalphaquantificationpreclinicalandclinicalapplicationsinalzheimersdisease
AT paquetclaire newhighlysensitiverodentandhumantestsforsolubleamyloidprecursorproteinalphaquantificationpreclinicalandclinicalapplicationsinalzheimersdisease
AT dumurgierjulien newhighlysensitiverodentandhumantestsforsolubleamyloidprecursorproteinalphaquantificationpreclinicalandclinicalapplicationsinalzheimersdisease
AT bourassetfanchon newhighlysensitiverodentandhumantestsforsolubleamyloidprecursorproteinalphaquantificationpreclinicalandclinicalapplicationsinalzheimersdisease
AT calonfrederic newhighlysensitiverodentandhumantestsforsolubleamyloidprecursorproteinalphaquantificationpreclinicalandclinicalapplicationsinalzheimersdisease
AT laplanchejeanlouis newhighlysensitiverodentandhumantestsforsolubleamyloidprecursorproteinalphaquantificationpreclinicalandclinicalapplicationsinalzheimersdisease
AT hugonjacques newhighlysensitiverodentandhumantestsforsolubleamyloidprecursorproteinalphaquantificationpreclinicalandclinicalapplicationsinalzheimersdisease
AT allinquantbernadette newhighlysensitiverodentandhumantestsforsolubleamyloidprecursorproteinalphaquantificationpreclinicalandclinicalapplicationsinalzheimersdisease